NLS Karolinska Development

Karolinska Development announces the promotion of its Chief Investment Officer Viktor Drvota to Deputy Chief Executive Officer. Drvota joined Karolinska Development as Chief Investment Officer in December 2015 from SEB Venture Capital, where he was Head of Life Science since 2002 and a senior investment manager. Prior to this he was a practising cardiologist at […]

Karolinska Development portfolio company OSSDSIGN presented preliminary data at European Congress of Neurosurgery 2016 in Athens, indicating that OSSDSIGN Cranial may provide better, more permanent solution for cranioplasty, even in a complex patient population. OSSDSIGN found, in a retrospective study of patients undergoing cranioplasty using OSSDSIGN Cranial, 96.7% of patients treated showed no signs of post-operative […]

Karolinska Development has published its Interim Report for the period January to March 2016. Significant events during Karolinska Development’s first quarter this year include Aprea raising SEK 437 million in a Series B financing round from a syndicate of specialist international life science investors. This was the largest ever completed by a Karolinska Development portfolio company and […]

Karolinska Development’s portfolio company Aprea has raised SEK 437 million ($51 million) in a Series B financing round – the largest private financing to date by one of its portfolio companies, and more broadly by any private life science company in Sweden in the last decade. The syndicate was co-led by specialist life sciences investors […]

Karolinska Development and Karolinska Institutet Holding AB, a company wholly owned by Karolinska Institutet (KI) have signed a new non-exclusive deal flow agreement. This agreement is a key element of a new strategy designed to improve the translation of medical innovations originating from KI into commercial enterprises that can generate value for all stakeholders. As part […]

Karolinska Development has appointed life science investor Viktor Drvota MD PhD as Chief Investment Officer. Terje Kalland MD PhD, the Company’s Deputy Chief Executive Officer and Chief Scientific Officer, will retire from both positions effective December 31, 2015. Dr Drvota joins Karolinska Development from SEB Venture Capital, where he has been Head of Life Science […]